Market Overview

UPDATE: Benchmark Raises PT on Cardiovascular Systems on Fiscal 2014 Estimates

Related CSII
Mid-Afternoon Market Update: Crude Oil Down 3.5%; Tesla Shares Rise Following Model 3 Launch
Mid-Day Market Update: US Stocks Turn Higher; Starwood Shares Drop Following Anbang Consoritum's Bailed Takeover

In a report published Friday, Benchmark Company analyst James Terwilliger reiterated his Speculative Buy rating on Cardiovascular Systems (NASDAQ: CSII), and raised his price target from $18.00 to $24.00.

In the report, Terwilliger noted, “We are publishing our fiscal 2014 revenue and EPS estimates of $125 million and ($0.78). This represents 25% revenue growth compared to our fiscal 2013 revenue estimate of $100 million. Our fiscal 2014 EPS estimate of ($0.78) compares favorably to our fiscal 2013 EPS estimate of ($1.09). The main driver of the improvement in our bottom line results is our assumption that CSII receives regulatory approval for their cardiology application with a subsequent launch in Q1:14 of calendar 2014.”

Cardiovascular Systems closed on Thursday at $20.30.

Latest Ratings for CSII

Apr 2016NeedhamUpgradesHoldBuy
Jan 2016NeedhamDowngradesUnderperform
Oct 2015Bank of AmericaDowngradesNeutralUnderperform

View More Analyst Ratings for CSII
View the Latest Analyst Ratings

Posted-In: Benchmark CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (CSII)

View Comments and Join the Discussion!